C₂N Diagnostics, a specialty diagnostics company with a vision to bring Clarity Through Innovation, has announced a partnership agreement with Mediford Corporation, a PHC Holdings Corporation Group Company and premier provider of clinical research to the biopharma industry throughout Japan.

The agreement greatly increases access to C₂N Biopharma Clinical Research Services, which offers highly sensitive mass spectrometry-based identification, quantification and monitoring of proteins, protein fragments (peptides) and other biomolecules implicated in human neurological diseases and overall brain health. 

The Mediford Corporation alliance means more researchers in Japan can access C₂N’s Precivity line of high-performance blood tests that aid in the diagnosis, prognosis, staging, and treatment monitoring of Alzheimer’s disease (AD), including Aβ42/40 and %p-tau217, and other proprietary biomarkers such as those that measure the microtubule-binding domain of tau protein (e.g., MTBR-tau).

The company’s latest innovation in the MTBR-tau biomarker intends to uniquely detect the presence and burden of neurofibrillary “tau” tangles (NFTs) comprised of aggregated tau proteins in the brain and as a potential alternative to invasive, costly and often inaccessible tau PET tracers.

In recognizing wide global interest in its services, C₂N has appointed Maki Hoshiko, PhD, as the lead for its Japan strategy and scientific collaborations. Hoshiko, who’s based in Kyoto, Japan, has a well-established background as a neuroscientist focused on the commercialisation aspects of the field. She previously served in a similar role with Biogen Inc.